



Prof. Dr. med. Stephan Brand

Gastroenterologie | Hepatologie · Dept. I

Kontakt

Prof. Dr. med. Stephan Brand
Rorschacher Str. 95
9007 St. Gallen
Switzerland

T +41 71 494 1064
stephan.brand@kssg.ch

Bereiche

Gastroenterologie | Hepatologie

Publikationen (143)

Woelfel S, Dütschler J, König M, Graf N, Oikonomou V, Krieger-Grübel C, Truniger S, Franke A, Eckhold A, Forsch K, Wyss J, Krupka N, Albrich W, Frei N, Geissler N, Schaub P, Friedrich M, Misselwitz B, Korte W, Bürgi J, Brand S. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2. *Aliment Pharmacol Ther* 2022; 57:103-116.

Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. *Therap Adv Gastroenterol* 2022; 15:17562848221074188.

Stallhofer J, Veith L, Diegelmann J, Probst P, Brand S, Schnitzler F, Olszak T, Török H, Mayerle J, Stallmach A, Beigel F. Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hcpidin and Intestinal Ceruloplasmin Expression. *Clin Transl Gastroenterol* 2022; 13:e00450.

Ruiz F, Wyss A, Rossel J, Sulz M, Brand S, Moncsek A, Mertens J, Roth R, Clottu A, Burri E, Juillerat P, Biedermann L, Greuter T, Rogler G, Pot C, Misselwitz B, Swiss IBD Cohort Study Group. A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. *Br J Pharmacol* 2021; 178:3157-3175.

Sawatzki M, Gueller U, Güsewell S, Husarik D, Semela D, Brand S. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. *J Hepatol* 2021; 74:419-427.

Misselwitz B, Rickenbacher A, Brand S. [Symptoms, diagnostic and therapy of perianal disease in patients with inflammatory bowel diseases]. *Ther Umsch* 2021; 78:547-558.

Sawatzki M, Guller U, Güsewell S, Husarik D, Semela D, Brand S. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. *Journal of hepatology* 2020; online

Vulliemoz M, Brand S, Juillerat P, Mottet C, Ben-Horin S, Michetti P, on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. *Digestion* 2020; 101 Suppl 1:16-26.

Schnitzler F, Friedrich M, Angelberger M, Diegelmann J, Stallhofer J, Wolf C, Dütschler J, Truniger S, Olszak T, Beigel F, Tillack C, Lohse P, Brand S. Development of a uniform, very aggressive disease phenotype in all homozygous carriers of the NOD2 mutation p.Leu1007fsX1008 with Crohn's disease and active smoking status resulting in ileal stenosis requiring surgery. *PloS one* 2020; 15:e0236421.

Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *J Crohns Colitis* 2020

Misselwitz B, Juillerat P, Sulz M, Siegmund B, Brand S, Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. *Digestion* 2020; 101 Suppl 1:69-82.

Brenig R, Antoniadou C, Wendon J, Heim M, Ludwig B, Weston C, Duong F, Semela D, Brand S, Boldanova T, Künzler-Heule P, Cupovic J, Besse L, Perez Shibayama C, Singanayagam A, Geng A, Triantafyllou E, Pop O, Bernsmeier C. Expression of AXL receptor tyrosine kinase relates to monocyte dysfunction and severity of cirrhosis. *Life Sci Alliance* 2019; 3

Sawatzki M, Meyenberger C, Brand S, Semela D. Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre. *Swiss Med Wkly* 2019; 149:w20087.

Sawatzki M, Semela D, Neuweiler J, Brand S (2018). Diagnosis of typical nodular hyperplasia in the liver - use of a novel ultrasonic vascular Doppler technique.

Frei N, Frei R, Semadeni G, Jochum W, Brand S, Borovicka J. Endoscopic Treatment of Early Barrett's Adenocarcinoma and Dysplasia: Focus on Submucosal Cancer. *Digestion* 2018; 99:293-300.

Sawatzki M, Semela D, Neuweiler J, Brand S (2017). Use of a Novel Ultrasonic Imaging Technique in the Diagnosis of Focal Nodular Hyperplasia . case series.

Török H, Bellon V, Konrad A, Lacher M, Tonenchi L, Siebeck M, Brand S, De Toni E. Functional Toll-Like Receptor (TLR)2 polymorphisms in the susceptibility to inflammatory bowel disease. *PloS one* 2017; 12:e0175180.

Li D, Devlin B, Sharma Y, Torkvist L, Targan S, Stempak J, Simms L, Regueiro M, Proctor D, Borneman J, Hakonarson H, McGovern D, Braun J, Cho J, Silverberg M, Rioux J, Brant S, Daly M, Xavier R, Milgrom R, Glas J, Halfvarson J, Radford-Smith G, Brand S, D'Amato M, Hui K, Jacobs J, Haritunians T, Achkar J, Niess J, Kugathasan S, Focchi C, Dubinsky M, Baidoo L, Aumais G, Ananthakrishnan A, Klei L, Schumm L, Büning C, Duerr R. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. *Gastroenterology* 2016; 151:724-32.

Flachsbar F, Brand S, Peters A, Strauch K, Müller-Nurasyid M, Hoffmann P, Nöthen M, Lieb W, Franke A, Schreiber S, Büning C, Galan P, Derbois C, Ellinghaus D, Gentschew L, Heinsen F, Caliebe A, Christiansen L, Nygaard M, Christensen K, Blanché H, Deleuze J, Nebel A. ImmunoChip analysis identifies association of the RAD50/IL13 region with human longevity. *Aging Cell* 2016; 15:585-8.

Lees C, van der Meulen-de Jong A, Theatre E, Schreiber S, Satsangi J, Lee J, Lawrance I, Kupcinkas L, Kennedy N, Weersma R, Wilson D, Barrett J, McGovern D, Radford-Smith G, Silverberg M, Mansfield J, Rioux J, Vermeire S, Parkes M, Huang H, Hov J, Halfvarson J, Annese V, Andrews J, Andersen V, Ahmad T, Zeissig S, Schumm L, Jostins L, Boucher G, Brand S, Brant S, Cho J, Hakonarson H, Goyette P, Geary R, Franke A, Ferguson L, Duerr R, Dubinsky M, Daly M, Cleyne I. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. *Lancet* 2015; 387:156-67.

Stallhofer J, Beigel F, Schnitzler F, Tillack-Schreiber C, Glas J, Lohse P, Wetzke M, Konrad-Zerna A, Friedrich M, Brand S. Lipocalin-2 Is a Disease Activity Marker in Inflammatory Bowel Disease Regulated by IL-17A, IL-22, and TNF- α and Modulated by IL23R Genotype Status. *Inflamm Bowel Dis* 2015; 21:2327-40.

Fischer A, Nöthen M, Herms S, Gieger C, Strauch K, Winkelmann J, Boehm B, Brand S, Büning C, Schürmann M, Ellinghaus E, Baurecht H, Lieb W, Nebel A, Müller-Quernheim J, Franke A, Schreiber S, Homolka J, Sterclova M, Ellinghaus D, Nutsua M, Hofmann S, Montgomery C, Iannuzzi M, Rybicki B, Petrek M, Mrazek F, Pabst S, Grohé C, Grunewald J, Ronninger M, Eklund A, Padyukov L, Mihailovic-Vucinic V, Jovanovic D. Identification of Immune-Relevant Factors Conferring Sarcoidosis Genetic Risk. *Am J Respir Crit Care Med* 2015; 192:727-36.

Schnitzler F, Grüner N, Rust C, Guba M, Denk G, Zachoval R, Göke B, Tillack C, Beigel F, Olszak T, Angelberger M, Wolf C, Karbalai N, Habicht A, Fischereider M, Schönermarck U, Stallhofer J, Friedrich M, Brand S. Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort. *PLoS one* 2015; 10:e0135807.

Schnitzler F, Lohse P, Glas J, Göke B, Beigel F, Tillack C, Olszak T, Diegelmann J, Angelberger M, Stallhofer J, Wolf C, Friedrich M, Brand S. The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations. *PLoS one* 2015; 10:e0116044.

Li J, Gieger C, Nöthen M, Büning C, Brand S, Sullivan K, Orange J, Fevang B, Schreiber S, Lieb W, Aukrust P, Chapel H, Cunningham-Rundles C, Franke A, Karlsen T, Grimbacher B, Hakonarson H, Hammarström L, Winkelmann J, Nair R, Elder J, Jørgensen S, Maggadottir S, Bakay M, Warnatz K, Glessner J, Pandey R, Salzer U, Schmidt R, Perez E, Resnick E, Goldacker S, Buchta M, Witte T, Padyukov L, Videm V, Folseraas T, Atschekzei F, Ellinghaus E. Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells. *Nat Commun* 2015; 6:6804.

Brand S. [Medical therapy of ulcerative colitis]. *MMW Fortschr Med* 2015; 157:45-8.

Baurecht H, Mrowietz U, Nair R, Nöthen M, Novak N, O'Regan G, Schreiber S, Smith C, Strauch K, Stuart P, Trembath R, Tsoi L, Weichenthal M, Barker J, Elder J, Weidinger S, Cordell H, Morris D, McLean W, Marenholz I, Hotze M, Brand S, Büning C, Cormican P, Corvin A, Ellinghaus D, Ellinghaus E, Esparza-Gordillo J, Fölster-Holst R, Franke A, Gieger C, Hübner N, Illig T, Irvine A, Kabesch M, Lee Y, Lieb W, Brown S. Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms. *Am J Hum Genet* 2015; 96:104-20.

Friedrich M, Diegelmann J, Schaubert J, Auernhammer C, Brand S. Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. *Mucosal Immunol* 2014; 8:943-58.

Schnitzler F, Lohse P, Glas J, Göke B, Stallhofer J, Tillack C, Beigel F, Olszak T, Diegelmann J, Angelberger M, Wolf C, Friedrich M, Brand S. The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067. *PLoS one* 2014; 9:e108503.

Friedrich M, Tillack C, Wollenberg A, Schaubert J, Brand S. IL-36 γ sustains a proinflammatory self-amplifying loop with IL-17C in anti-TNF-induced psoriasiform skin lesions of patients with Crohn's disease. *Inflamm Bowel Dis* 2014; 20:1891-901.

Friedrich M, Diegelmann J, Beigel F, Brand S. IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF- α -induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes. *Inflamm Bowel Dis* 2014; 20:1502-15.

Beigel F, Brand S, Göke B, Rust C, Breitenreicher S, Maul J, Lammert F, Howaldt S, Teich N, Ochsenkühn T. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. *J Crohns Colitis* 2014; 8:1471-9.

Beigel F, Deml M, Schnitzler F, Breitenreicher S, Göke B, Ochsenkühn T, Brand S. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. *PLoS one* 2014; 9:e99293.

Beigel F, Brand S, Seiderer J, Göke B, Laubender R, Van Steen K, John J, Breitenreicher S, Tillack C, Schnitzler F, Steinborn A, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. *Pharmacoepidemiol Drug Saf* 2014; 23:735-44.

Beigel F, Friedrich M, Probst C, Sotlar K, Göke B, Diegelmann J, Brand S. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members. *PLoS one* 2014; 9:e93498.

Olszak T, Nakajima A, Mizuguchi H, Kawasaki K, Nagata K, Müller W, Snapper S, Schreiber S, Kaser A, Zeissig S, Katayama K, Wada K, Neves J, Dowds C, Baker K, Glickman J, Davidson N, Lin C, Jobin C, Brand S, Sotlar K, Blumberg R. Protective mucosal immunity mediated by epithelial CD1d and IL-10. *Nature* 2014; 509:497-502.

Diegelmann J, Glas J, Franke A, Göke B, Bedynek A, Olszak T, Zimmermann E, Le Bras E, Czamara D, Brand S. Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2. *PLoS one* 2013; 8:e77773.

Steib C, Gmelin L, Pfeiler S, Schewe J, Brand S, Göke B, Gerbes A. Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. *Life Sci* 2013; 93:543-51.

Weidinger S, Duerr R, Boehm B, Illig T, Winkelmann J, Fölster-Holst R, Nöthen M, Hoffmann P, Zhang X, Yang S, Zuo X, Büning C, Brand S, Franke A, Lee Y, Schreiber S, Irvine A, McLean W, Brown S, Kabesch M, Fahy C, McAleer M, Glas J, Sun L, Elder J, Stuart P, Maintz L, Michel S, Novak N, Schaarschmidt H, Hübner N, Marenholz I, Matanovic A, Rodríguez E, Esparza-Gordillo J, Baurecht H, Werfel T, Meyer-Hoffert U, Tsoi L, Nakamura Y, Takahashi A, Kubo M, Tamari M, Hirota T, Herder C, Heim K, Prokisch H, Hotze M, Ellinghaus D. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. *Nat Genet* 2013; 45:808-12.

Franke A, Büning C, Duerr R, Nöthen M, Wang J, Vatn M, Mathew C, Sanderson J, Rutgeerts P, Vermeire S, McArdle W, Strachan D, Wijmenga C, Sans M, Brand S, Glas J, Parkes M, Schreiber S, Rosenstiel P, Subramani S, Karlsen T, Nothnagel M, Daly M, D'Amato M, Halfvarson J, Annese V, Latiano A, Illig T, Winkelmann J, Ponsioen C, Weersma R, Nikolaus S, Liu X, Doncheva N, Skieceviciene J, Rivas M, Keller A, Ellinghaus E, Bromberg Y, Stade B, Jiang T, Till A, Lipinski S, Zeissig S, Zhang H, Liu Q, Jiang F, Krawczak M, Kayser M, Kupcinskas L, Vogel U, Andersen V, Lee J, Berzuini C, Goodall J, Boehm B, Häslér R, Albrecht M, Mayr G, Forster M, Ellinghaus D. Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. *Gastroenterology* 2013; 145:339-47.

Thomsen I, Vatn M, Silverberg M, Duerr R, Padyukov L, Brand S, Sans M, Annese V, Achkar J, Melum E, Durie P, Sandford R, Mayr G, König I, Hveem K, Cleynen I, Gutierrez-Achury J, Ricaño-Ponce I, van Heel D, Björnsson E, Boberg K, Marschall H, Schreiber S, Manns M, Färkkilä M, Dale A, Chapman R, Lazaridis K, Franke A, Anderson C, Cho J, Bergquist A, Alexander G, Chazouillères O, Bowlus C, Wijmenga C, Schrupf E, Vermeire S, Albrecht M, Rioux J, Karlsen T, Næss S, Liu J, Gotthardt D, Pares A, Ellinghaus D, Shah T, Juran B, Milkiewicz P, Rust C, Schramm C, Hirschfield G, Invernizzi P, Eksteen B, Hov J, Folseraas T, Ellinghaus E, Rushbrook S, Doncheva N, Andreassen O, Weersma R, Weismüller T, Müller T, Srivastava B, Saarela J, Leppä V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich S, Thompson W, Mason A, Teufel A, Sterneck M, Dalekos G, Nöthen M, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen C, Croucher P, Schork A. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nat Genet* 2013; 45:670-5.

Tillack C, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schaubert J, Wollenberg A, Maier H, Wetzke M, Ehm L, Friedrich M, Laubender R, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon- γ -expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. *Gut* 2013; 63:567-77.

Brand S. Moving the genetics of inflammatory bowel diseases from bench to bedside: first steps towards personalised medicine. *Gut* 2013; 62:1531-3.

Glas J, Czamara D, Diegelmann J, Göke B, Friedrich M, Steib C, Beigel F, Wetzke M, Tsekeri E, Olszak T, Fries C, Stallhofer J, Bues S, Seiderer J, Brand S. IRGM variants and susceptibility to inflammatory bowel disease in the German population. *PLoS one* 2013; 8:e54338.

Glas J, Duerr R, Franke A, Kamboh M, Achkar J, Balschun T, Müller-Myhsok B, Wolf C, Olszak T, Wetzke M, Diegelmann J, Pasciuto G, Czamara D, Seiderer J, Brand S. PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF- κ B and XBP1 binding sites. *PloS one* 2012; 7:e52873.

Brand S, Ochsenkühn T, Hogardt M. Indigestion after Digestive Disease Week (DDW): be aware of the "Golden Raspberry Award" at DDW and *Cyclospora cayetanensis*. *Am J Gastroenterol* 2012; 107:1927-9.

Kupcinskas L, Potocnik U, Prescott N, Regueiro M, Rotter J, Russell R, Sanderson J, Sans M, Satsangi J, Schreiber S, Simms L, Sventoraityte J, Ponsioen C, Palmieri O, Kugathasan S, Latiano A, Laukens D, Lawrance I, Lees C, Louis E, Mahy G, Mansfield J, Morgan A, Mowat C, Newman W, Targan S, Taylor K, Tremelling M, Hakonarson H, Brant S, Radford-Smith G, Mathew C, Rioux J, Schadt E, Daly M, Franke A, Parkes M, Vermeire S, Barrett J, Annesse V, Silverberg M, Verspaget H, De Vos M, Wijmenga C, Wilson D, Winkelmann J, Xavier R, Zeissig S, Zhang B, Zhang C, Zhao H, Cho J, Karlsen T, Jostins L, Theatre E, Spain S, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar J, Ahmad T, Amininejad L, Ananthakrishnan A, Andersen V, Cleynen I, Ning K, Ripke S, Weersma R, Duerr R, McGovern D, Hui K, Lee J, Schumm L, Sharma Y, Anderson C, Essers J, Mitrovic M, Andrews J, Baidoo L, Balschun T, Ferguson L, Franchimont D, Franssen K, Geary R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Ellinghaus D, Edwards C, Bampton P, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney K, Dubinsky M, Hu X. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012; 491:119-24.

Zitzmann K, Vlotides G, Brand S, Lahm H, Spöttl G, Göke B, Auernhammer C. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. *Endocr Relat Cancer* 2012; 19:423-34.

Glas J, Czamara D, Diegelmann J, Ochsenkühn T, Göke B, Wetzke M, Steib C, Stallhofer J, Beigel F, Friedrich M, Tillack C, Fries C, Olszak T, Wagner J, Seiderer J, Brand S. Analysis of IL12B gene variants in inflammatory bowel disease. *PloS one* 2012; 7:e34349.

Glas J, Czamara D, Diegelmann J, Karbalai N, Ochsenkühn T, Göke B, Steib C, Friedrich M, Stallhofer J, Tillack C, Beigel F, Wetzke M, Olszak T, Seiderer J, Wagner J, Brand S. PTPN2 gene variants are associated with susceptibility to both Crohn's disease and ulcerative colitis supporting a common genetic disease background. *PloS one* 2012; 7:e33682.

Glas J, Czamara D, Diegelmann J, Friedrich M, Steib C, Beigel F, Olszak T, Tillack C, Fries C, Wetzke M, Bayrle C, Seiderer J, Brand S. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. *PloS one* 2011; 6:e29309.

Beigel F, Ochsenkühn T, Seiderer J, Göke B, Weidinger M, Breitenreicher S, Schnitzler F, Tillack C, Laubender R, Löhr B, Brand S. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. *Digestion* 2011; 85:47-54.

Diegelmann J, Olszak T, Göke B, Blumberg R, Brand S. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins. *J Biol Chem* 2011; 287:286-98.

Brand S. Homozygosity for the NOD2 p.Leu1007fsX1008 variant is the main genetic predictor for fibrostenotic Crohn's disease. *Inflamm Bowel Dis* 2011; 18:393-4.

Schnitzler F, Seiderer J, Stallhofer J, Brand S. Dominant disease-causing effect of NOD2 mutations in a family with all family members affected by Crohn's disease. *Inflamm Bowel Dis* 2011; 18:395-6.

Ehmann L, Tillack-Schreiber C, Brand S, Wollenberg A. Malignant melanoma during ustekinumab therapy of Crohn's disease. *Inflamm Bowel Dis* 2011; 18:E199-200.

Kasperek M, Bruckmeier A, Beigel F, Müller M, Brand S, Mansmann U, Jauch K, Ochsenkühn T, Kreis M. Infiximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery. *Inflamm Bowel Dis* 2011; 18:1207-13.

Rust C, Brand S. PSC: Protect and serve with colitis: does it help the liver to have severe ulcerative colitis?. *Gut* 2011; 60:1165-6.

Glas J, Czamara D, Diegelmann J, Müller-Myhsok B, Lohse P, Wolf C, Ochsenkühn T, Göke B, Lass U, Olszak T, Beigel F, Weidinger M, Pfennig S, Tillack C, Fries C, Seiderer J, Brand S. CEACAM6 gene variants in inflammatory bowel disease. *PloS one* 2011; 6:e19319.

Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender R, Auernhammer C. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. *Endocr Relat Cancer* 2011; 18:277-85.

Stallhofer J, Denk G, Glas J, Laubender R, Göke B, Rust C, Brand S, Pusch T. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis. *Digestion* 2011; 84:29-35.

Phillips A, van den Berg L, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson D, Westra H, Xavier R, Zhao Z, Ponsioen C, Andersen V, Torkvist L, Targan S, Steinhart A, Prescott N, Proctor D, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, Simms L, Seielstad M, Gazouli M, Anagnou N, Satsangi J, Cho J, Schreiber S, Daly M, Barrett J, Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr R, Vermeire S, Weersma R, Chamailard M, Brant S, Karlsen T, Kupcinskis L, Sventoraityte J, Mansfield J, Kugathasan S, Silverberg M, Halfvarson J, Rotter J, Mathew C, Griffiths A, Gearry R, Ahmad T, Rioux J, Panés J, Anderson C, Baldassano R, Barclay M, Bayless T, Brand S, Büning C, Colombel J, Denson L, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann R, Baidoo L, Bumpstead S, Boucher G, Lees C, Franke A, D'Amato M, Taylor K, Lee J, Goyette P, Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Floyd J, Florin T, Libioulle C, Louis E, McGovern D, Milla M, Montgomery G, Morley K, Mowat C, Ng A, Newman W, Ophoff R, Papi L, Palmieri O, Levine A, Lemann M, Franchimont D, Franke L, Georges M, Glas J, Glazer N, Guthery S, Haritunians T, Hayward N, Hugot J, Jobin G, Laukens D, Lawrance I, Peyrin-Biroulet L. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 2011; 43:246-52.

Beigel F, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF- α antibody-treated patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2011; 17:91-8.

Glas J, Czamara D, Diegelmann J, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Weidinger M, Laubender R, Olszak T, Jürgens M, Beigel F, Pfennig S, Tillack C, Seiderer J, Brand S. The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants. *PloS one* 2010; 5:e14466.

Diegelmann J, Beigel F, Zitzmann K, Kaul A, Göke B, Auernhammer C, Bartenschlager R, Diepolder H, Brand S. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. *PloS one* 2010; 5:e15200.

Glas J, Czamara D, Diegelmann J, Müller-Myhsok B, Folwaczny M, Ochsenkühn T, Göke B, Weidinger M, Olszak T, Beigel F, Wetzke M, Pfennig S, Tengler B, Fischer D, Seiderer J, Brand S. Pregnane X receptor (PXR/NR112) gene haplotypes modulate susceptibility to inflammatory bowel disease. *Inflamm Bowel Dis* 2010; 17:1917-24.

Glas J, Seiderer J, Tillack C, Paschos E, Wetzke M, Diegelmann J, Czamara D, Brand S. Functional SFTPD gene variants are not associated with susceptibility to inflammatory bowel disease in the German population. *Inflamm Bowel Dis* 2010; 17:1439-40.

Glas J, Mowat C, Newman W, Panés J, Phillips A, Proctor D, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Louis E, Libioulle C, Van Gossum A, Guthery S, Halfvarson J, Verspaget H, Hugot J, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Seibold F, Steinhart A, Mansfield J, Vermeire S, Duerr R, Silverberg M, Satsangi J, Schreiber S, Cho J, Annese V, Hakonarson H, Daly M, Griffiths A, Kugathasan S, Stokkers P, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan S, Brant S, Rioux J, D'Amato M, Weersma R, Parkes M, Franke A, Ellinghaus D, Festen E, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew C, Montgomery G, Prescott N, Bumpstead S, Bis J, McGovern D, Barrett J, Wang K, Radford-Smith G, Ahmad T, Lees C, Balschun T, Lee J, Roberts R, Anderson C, Raychaudhuri S, Rotter J, Colombel J, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Cohen A, Büning C, Schumm P, Sharma Y, Simms L, Taylor K, Whiteman D, Wijmenga C, Baldassano R, Barclay M, Bayless T, Brand S, Gearry R. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 2010; 42:1118-25.

Diegelmann J, Seiderer J, Niess J, Haller D, Göke B, Reinecker H, Brand S. Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation. *Inflamm Bowel Dis* 2010; 16:1871-81.

Schroepf S, Koletzko S, von Schweinitz D, Berger M, Ballauff A, Helmbrecht J, Hoster E, Glas J, Lohse P, Prell C, Brand S, Kappler R, Lacher M. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. *Inflamm Bowel Dis* 2010; 16:1882-90.

Glas J, Brand S. Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease. *Am J Gastroenterol* 2010;1206-1207.

Jürgens M, Ochsenkühn T, Göke B, Tillack C, Beigel F, Hasbargen U, Hübener C, Filik L, Brand S, Seiderer J. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. *Inflamm Bowel Dis* 2010; 16:1634-6.

Glas J, Roeske D, Diegelmann J, Müller-Myhsok B, Ochsenkühn T, Göke B, Paschos E, Wetzke M, Pfennig S, Markus C, Seiderer J, Brand S. Role of PPAR γ gene variants in inflammatory bowel disease. *Inflamm Bowel Dis* 2010; 17:1057-8.

Glas J, Roeske D, Müller-Myhsok B, Diegelmann J, Ochsenkühn T, Göke B, Folwaczny M, Lohse P, Epplen J, Klein W, Pfennig S, Weidinger M, Beigel F, Fries C, Nagy M, Seiderer J, Brand S. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. *PLoS one* 2010; 5:e10373.

Jürgens M, Herrmann K, Lohse P, Göke B, Kreis M, Schnitzler F, Weidinger M, Beigel F, Tillack C, Pfennig S, Wagner J, Wetzke M, Glas J, Seiderer J, Laubender R, Brand S, Ochsenkühn T. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype. *J Gastroenterol* 2010; 45:721-31.

Zitzmann K, Rüden J, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer C. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. *Cancer Lett* 2010; 295:100-9.

Ilowski M, Putz C, Weiss T, Brand S, Jauch K, Hengstler J, Thasler W. Augmenter of liver regeneration causes different kinetics of ERK1/2 and Akt/PKB phosphorylation than EGF and induces hepatocyte proliferation in an EGF receptor independent and liver specific manner. *Biochem Biophys Res Commun* 2010; 394:915-20.

Jürgens M, Ochsenkühn T, Glas J, Göke B, Lohse P, Tillack C, Schnitzler F, Stallhofer J, Pfennig S, Beigel F, Wetzke M, Wagner J, Seiderer J, Weidinger M, Hartl F, Laubender R, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. *Am J Gastroenterol* 2010; 105:1811-9.

Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S. The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. *PloS one* 2010; 5:e9453.

Beigel F, Jürgens M, Filik L, Bader L, Lück C, Göke B, Ochsenkühn T, Brand S, Seiderer J. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. *Inflamm Bowel Dis* 2009; 15:1240-4.

Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. *Gut* 2009; 58:1152-67.

Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. *Nat Rev Gastroenterol Hepatol* 2009; 6:433-6.

Török H, Müller-Myhsok B, Folwaczny C, Göke B, Folwaczny M, Ochsenkühn T, Lohse P, Klein W, Wetzke M, Teshome M, Tonenchi L, Endres I, Glas J, Brand S. Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. *Am J Gastroenterol* 2009; 104:1723-33.

Glas J, Müller-Myhsok B, Ochsenkühn T, Göke B, Lohse P, Folwaczny M, Koletzko S, Lacher M, Schiemann U, Griga T, Epplen J, Klein W, Pfennig S, Wetzke M, Ripke S, Stallhofer J, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. *Am J Gastroenterol* 2009; 104:1737-44.

Otte J, Zdebik A, Brand S, Chromik A, Strauss S, Schmitz F, Steintraesser L, Schmidt W. Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. *Regul Pept* 2009; 156:104-17.

Seiderer J, Brand S. IL-22: a two-headed cytokine in IBD?. *Inflamm Bowel Dis* 2009; 15:473-4.

Glas J, Klein W, Epplen J, Schiemann U, Mussack T, Lohse P, Göke B, Ochsenkühn T, Folwaczny M, Müller-Myhsok B, Griga T, Jürgens M, Stallhofer J, Seiderer J, Pasciuto G, Tillack C, Diegelmann J, Pfennig S, Konrad A, Schmechel S, Wetzke M, Török H, Brand S. rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. *Am J Gastroenterol* 2009; 104:665-72.

Otte J, Neumann H, Brand S, Schrader H, Schmidt W, Schmitz F. Expression of beta-defensin 4 is increased in human gastritis. *Eur J Clin Invest* 2009; 39:126-38.

Otte J, Mahjirian-Namari R, Brand S, Werner I, Schmidt W, Schmitz F. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. *Nutr Cancer* 2009; 61:103-13.

Seiderer J, Brand S, Kaser A. Sicherheit von anti-TNF-Antikörper-Therapien. In: Zytokine und chronisch-entzündliche Darmerkrankungen - Pathogenese und Therapie. Bremen: Uni-Med-Verlag, 2009.

Storr M, Emmerdinger D, Diegelmann J, Yüce B, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S. The role of fatty acid hydrolase gene variants in inflammatory bowel disease. *Aliment Pharmacol Ther* 2008; 29:542-51.

Beigel F, Nicolaus M, Denk G, Wagner A, Brand S. Bauchschmerzen nach dem Oktoberfest (Fallbericht zur Peritonealtuberkulose). *Gastroenterologie* 2008:144-146.

Tillack C, Seiderer J, Brand S, Göke B, Reiser M, Schaefer C, Diepolder H, Ochsenkühn T, Herrmann K. Correlation of magnetic resonance enteroclysis (MRE) and wireless capsule endoscopy (CE) in the diagnosis of small bowel lesions in Crohn's disease. *Inflamm Bowel Dis* 2008; 14:1219-28.

Otte J, Werner I, Brand S, Chromik A, Schmitz F, Kleine M, Schmidt W. Human beta defensin 2 promotes intestinal wound healing in vitro. *J Cell Biochem* 2008; 104:2286-97.

Beynon V, Glas J, Folwaczny C, Folwaczny M, Ochsenkühn T, Mussack T, Wagner S, Mair A, Lohse P, Brand S, Cotofana S, Török H. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. *Inflamm Bowel Dis* 2008; 14:1033-40.

Storr M, Patel K, Brand S, Göke B, Lutz B, Buckley N, Massa F, Sibaev A, Yüce B, Zhang H, Emmerdinger D, Keenan C, Sharkey K. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. *J Mol Med* 2008; 86:925-36.

Dambacher J, Beigel F, Zitzmann K, De Toni E, Göke B, Diepolder H, Auernhammer C, Brand S. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. *Gut* 2008; 58:1207-17.

Pusl T, Wild N, Vennegeerts T, Wimmer R, Göke B, Brand S, Rust C. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. *Biochem Biophys Res Commun* 2008; 371:441-5.

Seiderer J, Lohse P, Müller-Myhsok B, Ochsenkühn T, Göke B, Konrad A, Schmechel S, Jürgens M, Pfennig S, Tillack C, Stallhofer J, Glas J, Diegelmann J, Elben I, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. *Inflamm Bowel Dis* 2008; 14:437-45.

Schmechel S, Konrad A, Diegelmann J, Glas J, Wetzke M, Paschos E, Lohse P, Göke B, Brand S. Linking genetic susceptibility to Crohn's disease with Th17 cell function: IL-22 serum levels are increased in Crohn's disease and correlate with disease activity and IL23R genotype status. *Inflamm Bowel Dis* 2008; 14:204-12.

Seiderer J, Reinecker H, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Jürgens M, Pfennig S, Niess J, Glas J, Tillack C, Leistner D, Dambacher J, Brand S. Genotype-phenotype analysis of the CXCL16 p.Ala181Val polymorphism in inflammatory bowel disease. *Clin Immunol* 2008; 127:49-55.

Dambacher J, Beigel F, Zitzmann K, Heeg M, Göke B, Diepolder H, Auernhammer C, Brand S. The role of interleukin-22 in hepatitis C virus infection. *Cytokine* 2008; 41:209-16.

Glas J, Klein W, Epplen J, Folwaczny C, Lohse P, Göke B, Ochsenkühn T, Mussack T, Folwaczny M, Müller-Myhsok B, Griga T, Haller D, Pfennig S, Konrad A, Schmechel S, Dambacher J, Seiderer J, Schroff F, Wetzke M, Roeske D, Török H, Tonenchi L, Brand S. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. *Am J Gastroenterol* 2007; 103:682-91.

Brand S, Crispin A. C-reactive protein polymorphism and Crohn's disease (Letter to the Editors). *Aliment Pharmacol Ther* 2007; 25:520-521.

Glas J, Epplen J, Schiemann U, Folwaczny C, Lohse P, Göke B, Ochsenkühn T, Müller-Myhsok B, Folwaczny M, Mussack T, Klein W, Griga T, Maier K, Seiderer J, Wetzke M, Konrad A, Török H, Schmechel S, Tonenchi L, Grassl C, Dambacher J, Pfennig S, Brand S. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. *PLoS one* 2007; 2:e819.

Seiderer J, Lohse P, Ochsenkühn T, Göke B, Haller D, Török H, Konrad A, Pfennig S, Kühnlein B, Dambacher J, Brand S. The role of the selenoprotein S (SELS) gene -105G>A promoter polymorphism in inflammatory bowel disease and regulation of SELS gene expression in intestinal inflammation. *Tissue Antigens* 2007; 70:238-46.

Browning B, Liu X, Mathew C, Müller-Myhsok B, Newman W, Nimmo E, Noble C, Palmieri O, Parkes M, Petermann I, Rutgeerts P, Satsangi J, Shelling A, Siminovitsh K, Török H, Tremelling M, Vermeire S, Valvano M, Latiano A, Lakatos P, Lakatos L, Annese V, Barclay M, Bingham S, Brand S, Büning C, Castro M, Cucchiara S, Dallapiccola B, Drummond H, Ferguson L, Ferraris A, Fisher S, Geary R, Glas J, Henckaerts L, Huebner C, Knafelz D, Witt H. Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. *J Med Genet* 2007; 45:36-42.

Zitzmann K, Brand S, De Toni E, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. *Cancer Res* 2007; 67:5025-32.

Dambacher J, Beigel F, Seiderer J, Haller D, Göke B, Auernhammer C, Brand S. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. *Gut* 2007; 56:1257-65.

Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study. *Aliment Pharmacol Ther* 2007; 25:787-96.

Zitzmann K, De Toni E, Brand S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. *Neuroendocrinology* 2007; 85:54-60.

Brand S, Thasler W, Bilzer M, Diepolder H, Göke B, Storr M, Steib C, Olszak T, Prüfer T, Weiss T, Heeg M, Zitzmann K, Beigel F, Dambacher J, Auernhammer C. IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. *Am J Physiol Gastrointest Liver Physiol* 2007; 292:G1019-28.

Dambacher J, Lohse P, Ochsenkühn T, Göke B, Diebold J, Otte J, Tillack C, Konrad A, Hofbauer K, Pfennig S, Schnitzler F, Siscic Z, Seiderer J, Staudinger T, Brand S. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. *Inflamm Bowel Dis* 2007; 13:71-82.

Brand S, Ochsenkühn T, Göke B. Chronisch entzündliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa. In: *Gastroenterologie systematisch*. Bremen: Uni-Med-Verlag, 2007.

Seiderer J, Lohse P, Göke B, Sackmann M, Tillack C, Dambacher J, Hofbauer K, Herrmann K, Pfennig S, Staudinger T, Brand S, Schnitzler F, Ochsenkühn T. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. *Scand J Gastroenterol* 2006; 41:1421-32.

Seiderer J, Lohse P, Göke B, Schoenberg S, Pfennig S, Crispin A, Hatz R, Schnitzler F, Herrmann K, Brand S, Ochsenkühn T. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. *Inflamm Bowel Dis* 2006; 12:1114-21.

Thalmaier D, Lohse P, Ochsenkühn T, Göke B, Crispin A, Otte J, Pfennig S, Schachinger V, Konrad A, Seiderer J, Dambacher J, Brand S. The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the terminal ileum and decreased serum CRP levels in patients with Crohn's disease. *Aliment Pharmacol Ther* 2006; 24:1105-15.

Glas J, Folwaczny M, Ochsenkühn T, Brand S, Schnitzler F, Seiderer J, Lohse P, Schiemann U, Griga T, Epplen J, Klein W, Wetzke M, Mussack T, Müller-Myhsok B, Tonenchi L, Török H, Folwaczny C. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. *Inflamm Bowel Dis* 2006; 12:606-11.

Ochsenkühn T, Tillack C, Stepp H, Diebold J, Ott S, Baumgartner R, Brand S, Göke B, Sackmann M. Low frequency of colorectal dysplasia in patients with long-standing inflammatory bowel disease colitis: detection by fluorescence endoscopy. *Endoscopy* 2006; 38:477-82.

Seiderer J, Zech C, Diebold J, Schoenberg S, Brand S, Tillack C, Göke B, Ochsenkühn T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. *Eur J Gastroenterol Hepatol* 2006; 18:553-5.

Zitzmann K, Brand S, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer H, Auernhammer C. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. *Biochem Biophys Res Commun* 2006; 344:1334-41.

Brand S, Auernhammer C, Göke B, Ochsenkühn T, Seiderer J, Herrmann K, Leclair S, Popp A, Jagla W, Marquardt A, Diepolder H, Otte J, Eichhorst S, Zitzmann K, Olszak T, Beigel F, Dambacher J. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. *Am J Physiol Gastrointest Liver Physiol* 2006; 290:G827-38.

Brand S, Olszak T, Beigel F, Diebold J, Otte J, Eichhorst S, Göke B, Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. *J Cell Biochem* 2006; 97:709-23.

Schnitzler F, Ochsenkühn T, Göke B, Tillack C, Seiderer J, Hofbauer K, Pfennig S, Staudinger T, Brand S, Lohse P. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. *Immunogenetics* 2006; 58:99-106.

Brand S, Ochsenkühn T, Göke B, Konrad A, Tillack C, Seiderer J, Pfennig S, Staudinger T, Schnitzler F, Dambacher J, Hofbauer K, Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. *Am J Gastroenterol* 2006; 101:99-106.

Brand S, Dambacher J, Beigel F, Olszak T, Diebold J, Otte J, Göke B, Eichhorst S. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. *Exp Cell Res* 2005; 310:117-30.

Seiderer J, Schnitzler F, Brand S, Tillack C, Göke B, Ochsenkühn T. Infliximab zur Therapie chronisch entzündlicher Darmerkrankungen. *Dtsch Arztebl* 2005; 102:828-833.

Brand S, Auernhammer C, Adler B, Diepolder H, Göke B, Otte J, Eichhorst S, Zitzmann K, Olszak T, Beigel F, Dambacher J. The Novel Lambda-Interferons IL-28A and IL-29 Mediate Proinflammatory, Antiproliferative, and Antiviral Signals in Intestinal Epithelial Cells. *Gastroenterology* 2005; 129:371-371.

Brand S, Göke B, Auernhammer C, Adler B, Diepolder H, Diebold J, Otte J, Eichhorst S, Zitzmann K, Olszak T, Beigel F, Dambacher J. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. *Am J Physiol Gastrointest Liver Physiol* 2005; 289:G960-8.

Brand S, Lohse P, Göke B, Crispin A, Konrad A, Tillack C, Seiderer J, Dambacher J, Hofbauer K, Pfennig S, Schnitzler F, Staudinger T, Ochsenkühn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. *Inflamm Bowel Dis* 2005; 11:645-52.

Török H, Brännler G, Jagiello P, Epplen J, Griga T, Klein W, Schiemann U, Folwaczny M, Ochsenkühn T, Brand S, Tillack C, Glas J, Tonenchi L, Lohse P, Müller-Myhsok B, Limbersky O, Neugebauer C, Schnitzler F, Seiderer J, Folwaczny C. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. *Gut* 2005; 54:1421-7.

Brand S, Diepolder H, Göke B, Eichhorst S, Vlotides G, Olszak T, Beigel F, Dambacher J, Zitzmann K, Auernhammer C. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambda IL-28A and IL-29. *Biochem Biophys Res Commun* 2005; 331:543-8.

Niess J, Littman D, Fox J, Ploegh H, Boes M, Vyas J, McCormick B, Jung S, Landsman L, Gu X, Brand S, Reinecker H. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science* 2005; 307:254-8.

Vlotides G, Sörensen A, Kopp F, Zitzmann K, Cengic N, Brand S, Zachoval R, Auernhammer C. SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. *Biochem Biophys Res Commun* 2004; 320:1007-14.

Brand S, Wang T, Schomacker K, Poneris J, Lauwers G, Compton C, Pedrosa M, Nishioka N. Detection of high-grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. *Gastrointest Endosc* 2002; 56:479-87.

Brand S, Sakaguchi T, Gu X, Colgan S, Reinecker H. Fractalkine-mediated signals regulate cell-survival and immunomodulatory responses in intestinal epithelial cells. *Gastroenterology* 2002; 122:166-77.

Brand S, Reinecker H. Novel chemokine ligand-receptor targets for the treatment of intestinal inflammation. In: *Helicobacter meets inflammatory bowel disease*. Tokyo: Medical Tribune Inc., 2002.

Sakaguchi T, Brand S, Reinecker H. Mucosal barrier and immune mediators. *Curr Opin Gastroenterol* 2001; 17:573-7.

Poneris J, Brand S, Bouma B, Tearney G, Compton C, Nishioka N. Diagnosis of specialized intestinal metaplasia by optical coherence tomography. *Gastroenterology* 2001; 120:7-12.

Nishioka N, Brand S, Bouma B, Tearney G, Compton C. Optical coherence tomography in the gastrointestinal tract. In: *Handbook of Optical Coherence Tomography*. New York: Marcel Dekker Publ., 2001. S. 673-692.

Brand S, Poneris J, Bouma B, Tearney G, Compton C, Nishioka N. Optical coherence tomography in the gastrointestinal tract. *Endoscopy* 2000; 32:796-803.

Brand S, Strom T, Weber M, Schuffenhauer S, Murken J, Engelhardt D. [29-year-old patient with gynecomastia and small testis]. *Internist (Berl)* 1999; 40:437-41.

Brand S, Sackmann M, Paumgartner G, von Ritter C, Holl J, Baretton G, Baumgartner R, Ochsenkühn T, Stepp H, Baumgartner G. Detection of colonic dysplasia by light-induced fluorescence endoscopy: a pilot study. *Int J Colorectal Dis* 1999; 14:63-8.

Projekte (18)

VedolizumAb in IBD – Real-world non-Interventional, ProspEctive, ObservaTional StudY to describe real-world treatment patterns in patients on vedolizumab treatment

Klinische Forschung - 14.07.2022 - 31.12.2023

Laufend

I6T-MC-AMAX

Klinische Forschung - 07.06.2022 - 31.12.2024

Laufend

CDED Ernährungsstudie

Klinische Forschung - 01.06.2022 - 30.12.2023

Laufend

CED-4/CEL

Klinische Forschung - 01.06.2022 - 31.12.2024

Laufend

Amgen Efavaleukin Alfa

Klinische Forschung - 25.04.2022 - 31.12.2023

Laufend

Analysis of the effect of biological therapy on SARS-CoV-2-specific antibody levels following booster vaccination in patients with inflammatory bowel disease

Klinische Forschung - 20.01.2022 - 30.03.2023

Automatisch geschlossen

I6T-MC-AMBI

Klinische Forschung - 01.02.2021 - 01.01.2024

Abgeschlossen

I6T-MC-AMAP

Klinische Forschung - 29.01.2021 - 01.12.2024

Laufend

APD334-206 Etrasimod

Klinische Forschung - 01.10.2020 - 01.12.2022

Abgeschlossen

<p>M14-675 <i>Klinische Forschung - 01.01.2019 - 01.08.2020</i> <i>Abgeschlossen</i></p>
<p>I6T-MC-AMAM <i>Klinische Forschung - 01.01.2019 - 01.12.2022</i> <i>Automatisch geschlossen</i></p>
<p>I6T-MC-AMAN <i>Klinische Forschung - 01.01.2018 - 01.02.2021</i> <i>Abgeschlossen</i></p>
<p>I6T-MC-AMBG <i>Klinische Forschung - 01.01.2018 - 01.06.2021</i> <i>Automatisch geschlossen</i></p>
<p>ACRE <i>Klinische Forschung - 01.01.2018 - 01.07.2021</i> <i>Abgeschlossen</i></p>
<p>GA29144/Bergamot <i>Klinische Forschung - 01.08.2017 - 01.08.2021</i> <i>Automatisch geschlossen</i></p>
<p>M14-533 <i>Klinische Forschung - 01.01.2017 - 01.12.2022</i> <i>Automatisch geschlossen</i></p>
<p>Entyvio PASS Study <i>Klinische Forschung - 28.07.2016 - 28.06.2022</i> <i>Automatisch geschlossen</i></p>
<p>Swiss EoE cohort <i>Grundlagenforschung - 01.01.2006 - 31.12.2030</i> <i>Laufend</i></p>